PepLib

PepLib is a high-tech biopharmaceutical startup focused on revolutionizing the discovery of new peptide drugs. Established in 2017, PepLib is based in Zhuzhou, China, with a subsidiary in New Jersey, USA. The company's core platform, Peptide Information Compression Technology (PICT), boasts a groundbreaking ZSenithFive® peptide library, containing information on nearly half a billion peptides. In addition to PICT, PepLib has developed 4 complementary peptide discovery platforms, enhancing its capabilities for peptide drug discovery. Securing Series Pre-A financing of 100 million yuan (USD 16 million) in 2019 and Series A financing of 220 million yuan (USD 35 million) in 2021, PepLib is now aiming for Series Pre-IPO financing. With over 190 employees, more than 80% of which are dedicated to research and development, the company is committed to advancing innovation in the treatment of oncology and cardiometabolic diseases. Notably, their oncology programs are focused on the development of peptide drug conjugates (PDCs) and peptide radionuclide conjugates (PRCs). PepLib's recent Series A investment on 30th April 2021 attracted significant funding from investors including Cowin Capital, HighLight Capital, Legend Star, CAS Investment Management, 澳银资本, and Fortune Capital. With a strong financial backing and a focus on critical therapeutic areas, PepLib is poised to make a substantial impact in the biotechnology and healthcare industries.